Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.02
VRX's Cash to Debt is ranked lower than
57% of the 1158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. VRX: 0.02 )
VRX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.02

Equity to Asset 0.20
VRX's Equity to Asset is ranked lower than
52% of the 965 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. VRX: 0.20 )
VRX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.85
Current: 0.2

0.18
0.85
Interest Coverage 2.10
VRX's Interest Coverage is ranked lower than
56% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 236.52 vs. VRX: 2.10 )
VRX' s 10-Year Interest Coverage Range
Min: 0.12   Max: 121.91
Current: 2.1

0.12
121.91
F-Score: 6
Z-Score: 2.58
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.75
VRX's Operating margin (%) is ranked higher than
93% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. VRX: 24.75 )
VRX' s 10-Year Operating margin (%) Range
Min: -9.32   Max: 45.51
Current: 24.75

-9.32
45.51
Net-margin (%) 11.21
VRX's Net-margin (%) is ranked higher than
82% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.46 vs. VRX: 11.21 )
VRX' s 10-Year Net-margin (%) Range
Min: -47.86   Max: 42.72
Current: 11.21

-47.86
42.72
ROE (%) 18.05
VRX's ROE (%) is ranked higher than
89% of the 1135 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.08 vs. VRX: 18.05 )
VRX' s 10-Year ROE (%) Range
Min: -59.65   Max: 88.03
Current: 18.05

-59.65
88.03
ROA (%) 3.41
VRX's ROA (%) is ranked higher than
71% of the 1169 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. VRX: 3.41 )
VRX' s 10-Year ROA (%) Range
Min: -18.92   Max: 47.04
Current: 3.41

-18.92
47.04
ROC (Joel Greenblatt) (%) 78.79
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.30 vs. VRX: 78.79 )
VRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.66   Max: 291.4
Current: 78.79

-50.66
291.4
Revenue Growth (3Y)(%) 53.40
VRX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 948 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. VRX: 53.40 )
VRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.8   Max: 82.1
Current: 53.4

-10.8
82.1
EBITDA Growth (3Y)(%) 64.00
VRX's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 846 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. VRX: 64.00 )
VRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.7   Max: 113
Current: 64

-35.7
113
EPS Growth (3Y)(%) 83.10
VRX's EPS Growth (3Y)(%) is ranked higher than
98% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. VRX: 83.10 )
VRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.2   Max: 100.6
Current: 83.1

-37.2
100.6
» VRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

VRX Guru Trades in Q2 2014

Joel Greenblatt 6,172 sh (New)
Louis Moore Bacon 127,422 sh (+1589.05%)
Diamond Hill Capital 147,867 sh (+403.46%)
George Soros 472,187 sh (+185.46%)
Andreas Halvorsen 11,830,932 sh (+27.27%)
Chris Davis 3,153,748 sh (+16.03%)
Steve Mandel 10,089,450 sh (+14.44%)
Jean-Marie Eveillard 1,024,402 sh (+13.50%)
Lee Ainslie 2,625,014 sh (+8.39%)
Glenn Greenberg 6,050,442 sh (+8.19%)
Ruane Cunniff 34,298,384 sh (+0.24%)
Lou Simpson 1,615,549 sh (+0.06%)
Jeff Ubben 18,923,877 sh (unchged)
Steven Cohen 1,528,606 sh (unchged)
Mariko Gordon Sold Out
Pioneer Investments Sold Out
Jim Simons Sold Out
Daniel Loeb Sold Out
Private Capital 300,446 sh (-1.02%)
Wallace Weitz 1,551,076 sh (-2.91%)
John Paulson 500,300 sh (-49.97%)
Jeremy Grantham 45,552 sh (-70.16%)
» More
Q3 2014

VRX Guru Trades in Q3 2014

Jana Partners 1,284,184 sh (New)
Paul Tudor Jones 6,826 sh (New)
George Soros 626,748 sh (+32.73%)
Diamond Hill Capital 173,012 sh (+17.01%)
Lou Simpson 1,815,916 sh (+12.40%)
Chris Davis 3,529,237 sh (+11.91%)
Wallace Weitz 1,691,525 sh (+9.05%)
Steve Mandel 10,985,940 sh (+8.89%)
Glenn Greenberg 6,586,582 sh (+8.86%)
John Paulson 520,700 sh (+4.08%)
Ruane Cunniff 34,494,015 sh (+0.57%)
Jeff Ubben 18,923,877 sh (unchged)
Steven Cohen 523,400 sh (unchged)
Joel Greenblatt Sold Out
Private Capital 296,871 sh (-1.19%)
Jean-Marie Eveillard 1,010,802 sh (-1.33%)
Lee Ainslie 2,527,896 sh (-3.70%)
Andreas Halvorsen 9,967,690 sh (-15.75%)
Steven Cohen 1,056,700 sh (-30.87%)
Jeremy Grantham 23,705 sh (-47.96%)
Louis Moore Bacon 30,544 sh (-76.03%)
» More
Q4 2014

VRX Guru Trades in Q4 2014

Jim Simons 38,989 sh (New)
Joel Greenblatt 295,632 sh (New)
Jeremy Grantham 1,042,191 sh (+4296.50%)
Paul Tudor Jones 100,000 sh (+1364.99%)
Jana Partners 4,307,534 sh (+235.43%)
Jean-Marie Eveillard 1,191,832 sh (+17.91%)
Jeff Ubben 19,383,877 sh (+2.43%)
Jeff Ubben 19,383,877 sh (+1.30%)
John Paulson 520,700 sh (unchged)
Ruane Cunniff 34,331,973 sh (unchged)
Ruane Cunniff 34,331,973 sh (-0.47%)
Chris Davis 3,508,163 sh (-0.60%)
Diamond Hill Capital 171,513 sh (-0.87%)
Lou Simpson 1,794,227 sh (-1.19%)
Private Capital 292,802 sh (-1.37%)
George Soros 606,587 sh (-3.22%)
Lee Ainslie 2,423,766 sh (-4.12%)
Glenn Greenberg 6,126,609 sh (-6.98%)
Andreas Halvorsen 9,077,007 sh (-8.94%)
Wallace Weitz 1,378,606 sh (-18.50%)
Steve Mandel 8,250,886 sh (-24.90%)
Louis Moore Bacon 14,286 sh (-53.23%)
Steven Cohen 132,300 sh (-87.48%)
» More
Q1 2015

VRX Guru Trades in Q1 2015

Bill Ackman 19,473,933 sh (unchged)
Ruane Cunniff 34,083,713 sh (-0.72%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Valeant Pharmaceuticals International Inc

Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc - Jul 25, 2014

We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Sequoia Fund's Discussion of Valeant Pharmaceuticals - Mar 07, 2014

Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million.



Cash earnings per share have probably more than tripled over the last four years. While we do not expect this growth trajectory to continue at such a rapid pace in the future, we do believe the company can continue to produce positive organic growth supplemented by ongoing acquisitions that will enable Valeant to grow cash earnings per share at an above-average rate.



We like Valeant’s approach to the pharmaceutical business. It has acquired a diverse stable of branded, generic and OTC drugs and, more recently, medical devices including dermal fillers and contact lenses. Many of its products are steady sellers in specialty categories like dermatology and ophthalmology. In our view, Valeant is essentially a value investor in health care products.





Source: Sequoia Fund's 2013 Annual Report - Management's Discussion of Fund Performance



Check out Sequoia Fund latest stock trades

Wallace Weitz Comments on Valeant Pharmaceuticals - Jul 15, 2013

Valeant (VRX--$86)(VRX) Valeant Pharmaceuticals continues to make acquisitions (most recently agreeing to purchase Bausch and Lomb), wring cost savings from the combined operations, and grow earnings per share. The outlook for Valeant’s well-diversified portfolio of 1,100 products is relatively predictable. The company has a robust pipeline of acquisition candidates and we expect Valeant to build on its dermatology and eye care franchises over the next few years.

From Wallace Weitz’s second quarter 2013 letter to shareholders.


Check out Wallace Weitz latest stock trades

Top Ranked Articles about Valeant Pharmaceuticals International Inc

The Top Guru-Held Canadian Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Ruane, Cunniff & Goldfarb Inc Comments on Valeant
A topic many shareholders and clients wanted to discuss with us in 2014 was Valeant (VRX). It is the largest holding in Sequoia by far. One could argue Valeant wasted much of the year on a quixotic effort to buy Allergan (AGN), maker of Botox. Allergan had no interest in being acquired and fought a vicious and savvy public relations campaign to portray Valeant as unworthy of marriage to such a prized catch. In the end, Allergan found a suitor more to its liking in Actavis (ACT), and Actavis agreed to pay a substantially higher price than Valeant had offered. Read more...
Jeff Ubben Deals in Only Four Companies in Fourth Quarter
Jeff Ubben (Trades, Portfolio), founder, chief executive officer and chief investment officer of ValueAct Holding LP, made multiple buys and sells of stocks in just four companies in the fourth quarter. That isn’t typical. Normally, he buys and sells stocks in many companies in a quarter but usually once, rarely on multiple occasions. Read more...
Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectivity
If you don’t know Lou Simpson (Trades, Portfolio), you should. He was the former investment manager at GEICO and Warren Buffett (Trades, Portfolio) spoke highly about him many times. Mr. Simpson just reported his third quarter portfolio. He buys Liberty Global PLC, Valeant Pharmaceuticals International Inc, U.S. Bancorp, Charles Schwab Corp, Brookfield Asset Management Inc, Oracle Corporation, Wells Fargo & Co, Berkshire Hathaway Inc, Crown Holdings Inc, sells TE Connectivity Ltd during the 3-months ended 09/30/2014, according to the most recent filings of his investment company, SQ Advisors, LLC. As of 09/30/2014, SQ Advisors, LLC owns 13 stocks with a total value of $2.6 billion. These are the details of the buys and sells. Read more...
Most Held Canadian Stocks of the Second Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc
We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 85.10
VRX's P/E(ttm) is ranked higher than
67% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.40 vs. VRX: 85.10 )
VRX' s 10-Year P/E(ttm) Range
Min: 5.91   Max: 661.18
Current: 85.1

5.91
661.18
Forward P/E 11.90
VRX's Forward P/E is ranked higher than
97% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 11.90 )
N/A
PE(NRI) 83.30
VRX's PE(NRI) is ranked higher than
71% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 59.00 vs. VRX: 83.30 )
VRX' s 10-Year PE(NRI) Range
Min: 5.9   Max: 631.79
Current: 83.3

5.9
631.79
P/B 14.40
VRX's P/B is ranked lower than
57% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. VRX: 14.40 )
VRX' s 10-Year P/B Range
Min: 1.03   Max: 14.4
Current: 14.4

1.03
14.4
P/S 8.70
VRX's P/S is ranked lower than
51% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.25 vs. VRX: 8.70 )
VRX' s 10-Year P/S Range
Min: 1.61   Max: 9.64
Current: 8.7

1.61
9.64
PFCF 42.70
VRX's PFCF is ranked higher than
82% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 42.70 )
VRX' s 10-Year PFCF Range
Min: 2.67   Max: 281.44
Current: 42.7

2.67
281.44
POCF 33.26
VRX's POCF is ranked higher than
79% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.00 vs. VRX: 33.26 )
VRX' s 10-Year POCF Range
Min: 4.05   Max: 48.31
Current: 33.26

4.05
48.31
EV-to-EBIT 44.71
VRX's EV-to-EBIT is ranked higher than
74% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. VRX: 44.71 )
VRX' s 10-Year EV-to-EBIT Range
Min: -5795.6   Max: 2482.6
Current: 44.71

-5795.6
2482.6
PEG 1.49
VRX's PEG is ranked higher than
94% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 1.49 )
VRX' s 10-Year PEG Range
Min: 0.76   Max: 249.44
Current: 1.49

0.76
249.44
Shiller P/E 3358.60
VRX's Shiller P/E is ranked higher than
70% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 3358.60 )
VRX' s 10-Year Shiller P/E Range
Min: 7.93   Max: 3365.4
Current: 3358.6

7.93
3365.4
Current Ratio 1.54
VRX's Current Ratio is ranked higher than
60% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.23 vs. VRX: 1.54 )
VRX' s 10-Year Current Ratio Range
Min: 0.91   Max: 6.13
Current: 1.54

0.91
6.13
Quick Ratio 1.19
VRX's Quick Ratio is ranked higher than
61% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. VRX: 1.19 )
VRX' s 10-Year Quick Ratio Range
Min: 0.78   Max: 5.66
Current: 1.19

0.78
5.66
Days Inventory 149.69
VRX's Days Inventory is ranked higher than
68% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 141.66 vs. VRX: 149.69 )
VRX' s 10-Year Days Inventory Range
Min: 89.42   Max: 333.93
Current: 149.69

89.42
333.93
Days Sales Outstanding 94.97
VRX's Days Sales Outstanding is ranked higher than
69% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. VRX: 94.97 )
VRX' s 10-Year Days Sales Outstanding Range
Min: 43.41   Max: 146.62
Current: 94.97

43.41
146.62

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 5.80
VRX's Price/DCF (Projected) is ranked higher than
80% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 5.80 )
VRX' s 10-Year Price/DCF (Projected) Range
Min: 0.38   Max: 8.81
Current: 5.8

0.38
8.81
Price/Median PS Value 2.40
VRX's Price/Median PS Value is ranked higher than
57% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. VRX: 2.40 )
VRX' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 4.81
Current: 2.4

0.58
4.81
Price/Peter Lynch Fair Value 3.40
VRX's Price/Peter Lynch Fair Value is ranked higher than
91% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 3.40 )
VRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 5.8
Current: 3.4

0.8
5.8
Earnings Yield (Greenblatt) 2.20
VRX's Earnings Yield (Greenblatt) is ranked higher than
68% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. VRX: 2.20 )
VRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 20.6
Current: 2.2

0.1
20.6
Forward Rate of Return (Yacktman) 61.70
VRX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.49 vs. VRX: 61.70 )
VRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 62.5
Current: 61.7

2.5
62.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico,
Valeant Pharmaceuticals International Inc was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act effective June 29, 2005. In connection with the acquisition of Valeant Pharmaceuticals International (Valeant) in September 2010, Biovail was renamed Valeant Pharmaceuticals International, Inc. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products OTC, and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.
» More Articles for VRX

Headlines

Articles On GuruFocus.com
Submit Questions for Upcoming Q&A With Value Investor Wally Weitz Apr 24 2015 
Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
The Top Guru-Held Canadian Stocks Apr 11 2015 
Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
Pershing Square Holdings: First Annual Report Mar 25 2015 
This Week’s Pharma Highlights Mar 19 2015 
Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
Valeant Pharma Acquires Salix Mar 18 2015 
Ruane, Cunniff & Goldfarb Inc Comments on Valeant Mar 16 2015 
Ruane, Cunniff & Goldfarb’s Sequoia Fund Q4 2014 Shareholder Letter Mar 16 2015 


More From Other Websites
Endo International, a New Position for OZ Management Apr 24 2015
Will Ecolab's (ECL) Q1 Earnings Disappoint Estimates? - Analyst Blog Apr 24 2015
Valeant Pharmaceuticals Intl Inc (VRX), Apple Inc. (AAPL), McDonald’s Corporation (MCD): A Look At... Apr 24 2015
Teva, Mylan and Perrigo: Which Combination is Most Likely? Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
9:15 am Valeant Pharma confirms that RELISTOR has received a positive CHMP opinion in the EU to... Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation... Apr 24 2015
Will the Salix-Valeant story play out over and over again? Apr 23 2015
LLY CFO: Here's what's driving profits Apr 23 2015
Meet Pharma’s Newest Movers and Shakers Apr 22 2015
Lone Pine Reduces Its Stake in Valeant Pharmaceuticals Apr 22 2015
Are M&A Replacing R&D In Pharma? Apr 22 2015
Mylan plays monkey-in-the-middle of hostile takeover battles Apr 21 2015
Teva Pharmaceutical offers to buy Mylan for $40.1 bn Apr 21 2015
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog Apr 21 2015
Teva Pharmaceuticals Hopes $40 Billion Mylan Deal Will Fuel Stock Rebound Apr 21 2015
Billionaire Andreas Halvorsen’s New Healthcare Pick Apr 20 2015
Will St. Jude Medical's (STJ) Earnings Miss the Mark in Q1? - Analyst Blog Apr 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK